Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2

Investigational New Drugs

Volumn 32, Issue 1, 2014, Pages 160-170

  LoRusso, Patricia ^a   Venkatakrishnan, Karthik ^b   Chiorean, E Gabriela ^c,e   Noe, Dennis ^b   Wu, Jing Tao ^b   Sankoh, Serap ^b   Corvez, Maria ^b   Sausville, Edward A ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e USA   (United States)

Author keywords

Brain metastases; Breast cancer; EGFR; HER2; Pharmacokinetics

Indexed keywords

ADULT; AGED; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYBUTYRATES; MALE; MIDDLE AGED; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84899105729     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9988-x     Document Type: Article

References (36)

1. Baselga J (2010) Treatment of HER2-overexpressing breast cancer. Ann Oncol 21:vii36-vii40. doi:10.1093/annonc/mdq421
2. Bianco R, Melisi D, Ciardiello F, Tortora G (2006) Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 42:290-294 (Pubitemid 43132883)
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182. doi:10.1126/science.3798106 (Pubitemid 17231334)
4. Jackisch C (2006) HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 11:34-41. doi:10.1634/theoncologist.11- 90001-34
5. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726. doi:10.1200/JCO.20.3.719 (Pubitemid 34111379)
6. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792. doi:10.1056/NEJM200103153441101 (Pubitemid 32222155)
7. Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648 (Pubitemid 29415219)
8. Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8:215. doi:10.1186/bcr1612
9. Lin NU, Winer EP (2007) Brainmetastases: the HER2 paradigm. Clin Cancer Res 13:1648-1655. doi:10.1158/1078-0432.CCR-06-2478
10. Contessa JN, Hamstra DA (2008) Revoking the privilege: targeting HER2 in the central nervous system. Mol Pharmacol 73:271-273. doi:10.1124/mol.107.042986 (Pubitemid 351159198)
11. Polli JW, Olson KL, Chism JP et al (2009) An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl] amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37:439-442. doi:10.1124/dmd.108.024646
12. Taskar KS, Rudraraju V, Mittapalli RK et al (2012) Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 29:770-781. doi:10.1007/s11095-011-0601-8
13. Lin NU, Carey LA, Liu MC et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993-1999. doi:10.1200/JCO.2007.12. 3588
14. Lin NU, Dieras V, Paul D et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452-1459. doi:10.1158/1078-0432.CCR-08-1080
15. Neuwelt EA (2004) Mechanisms of disease: the blood-brain barrier. Neurosurgery 54:131-140, discussion 141-132
16. Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295-2305. doi:10.1200/JCO.2006.09.9861 (Pubitemid 46954658)
17. Deeken JF, Loscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663-1674. doi:10.1158/1078-0432.CCR-06-2854 (Pubitemid 46952931)
18. Ishikawa T, Seto M, Banno H et al (2011) Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem 54:8030-8050. doi:10.1021/jm2008634
19. Takagi S, Hayashi A, Ohta Y (2009) HER2 and HER3 cooperatively regulate tumor cell growth and determine sensitivity to the HER kinase inhibitor TAK-285. Cancer Res 69(2 Suppl 1):Abstract 3155. doi: 10.1158/0008-5472.SABCS-3155
20. Aertgeerts K, Skene R, Yano J et al (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 286:18756-18765. doi:10.1074/jbc.M110.206193
21. Shell S, Pry K, Trusk P et al (2008) Novel inhibitory mechanisms of TAK-285, a new EGFR/ErbB2 dual inhibitor. Eur J Cancer 6:100, Abstract 313
22. Iwahara A, Tamura T, Takagi S, Kamiguchi H, Yusa T, Ohta Y (2008) In vivo antitumor efficacy of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor. Eur J Cancer 6:99-100. doi:10.1016/S1359-6349(08)72245-6, Abstract 311
23. Wu J-T, Gordon J, Liao M et al. (2011) Comparison of various nonclinical in vivo/in vitro models to assess CNS penetration of TAK-285, a novel HER2/EGFR inhibitor. Abstract P93. Presented at the 17th North American Regional ISSX Meeting; Atlanta, GA; October 16-20, 2011
24. Erdo F, Gordon J, Wu JT, Sziraki I (2012) Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats. Brain Res Bull 87:413-419. doi:10.1016/j.brainresbull.2012.01.002
25. Doi T, Takiuchi H, Ohtsu A et al (2012) Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. Br J Cancer 106:666-672. doi:10.1038/bjc.2011.590
26. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216. doi:10.1093/jnci/92.3.205
27. Chiorean EG, Sausville EA, Heath EI et al. (2011) Phase 1 study of TAK-285, an investigational HER2/EGFR inhibitor, in patients with advanced cancer: updated results and assessment of human CSF distribution. J Clin Oncol 29(suppl). Abstract 2538
28. Moy B, Goss PE (2007) Lapatinib-associated toxicity and practical management recommendations. Oncologist 12:756-765. doi:10.1634/theoncologist.12- 7-756 (Pubitemid 47328219)
29. Roy V, Perez EA (2009) Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist 14:1061-1069. doi:10.1634/theoncologist.2009-0142
30. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF (2011) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13:e17. doi:10.1017/S1462399411001888
31. Yonemori K, Tsuta K, Ono M et al (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 116:302-308. doi:10.1002/cncr.24735
32. Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119. doi:10.1056/NEJMoa1113216
33. U.S. Food and Drug Administration (2013) FDA approves Perjeta for type of late-stage breast cancer (2012). http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm307549.htm. Accessed 23 Jan 2013
34. Krop IE, Lorusso P, Miller KD et al (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30:3234-3241. doi:10.1200/JCO.2011.40.5902
35. Blackwell K, Miles D, Gianni L et al. (2013) EMILIA: T-DM1 demonstrates greater safety, efficacy for advanced HER2-positive breast cancer (summary of 2012 ASCO oral presentation). http://chicago2012.asco.org/ASCODailyNews/LBA1. aspx. Accessed 23 Jan 2013
36. Blackwell KL, Miles D, Gianni L et al. (2012) Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 30(suppl).Abstract LBA1